Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19463708 | 1.00 | HDAC6 (0.43) | HDAC6ALDH1A1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL30910298 | 0.93 | HDAC6 (0.44) | HDAC6ALDH1A1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL28349581 | 0.93 | HDAC6 (0.44) | HDAC6ALDH1A1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL24383374 | 0.85 | KMT2A (0.43) | HDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL28349578 | 0.80 | MEN1 (0.45) | HDAC6ALDH1A1CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL20996163 | 0.80 | GAA (0.42) | HDAC6ALDH1A1SMN1; SMN2HDAC3HDAC1 | |
| SCHEMBL20996162 | 0.80 | GAA (0.42) | HDAC6ALDH1A1SMN1; SMN2HDAC3HDAC1 | |
| SCHEMBL19463263 | 0.80 | GAA (0.42) | HDAC6ALDH1A1SMN1; SMN2HDAC3HDAC1 | |
| SCHEMBL24383281 | 0.78 | ALDH1A1 (0.44) | HDAC6ALDH1A1SMN1; SMN2 | |
| SCHEMBL25713808 | 0.77 | KIF11 (0.51) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179496-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250099594-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2025-03-27 | — | — | US | disclosed |
| US-20240245784-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2024-07-25 | — | — | US | disclosed |
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-11896672-B2 | Targeted nucleic acid conjugate compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-13 | — | — | US | disclosed |
| US-20230110295-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-04-13 | — | — | US | disclosed |
| US-11427823-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-08-30 | — | — | US | disclosed |
| EP-3950004-A1 | TARGETED COMPOSITIONS | Arbutus Biopharma Corporation (CA) | 2022-02-09 | — | — | EP | disclosed |
| US-20220031847-A1 | THERAPEUTIC METHODS | GENEVANT SCIENCES GMBH (CH) | 2022-02-03 | — | — | US | disclosed |
| US-20200407724-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-12-31 | — | — | US | disclosed |
| US-20190160176-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-05-30 | — | — | US | disclosed |
| WO-2019051257-A2 | METHODS FOR TREATING HEPATITIS B INFECTIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-03-14 | — | — | WO | disclosed |
| EP-3443092-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | Arbutus Biopharma Corporation (CA) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017177326-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190160176-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | HAVCR2, DCTD, POLRMT | HDAC6 2204/4885ALDH1A1 2585/4885CYP3A4 4125/4885 |
| US-20250099594-A1 | TARGETED COMPOSITIONS | HAVCR2, HDGF, NR1H4 | HDAC6 2125/4885ALDH1A1 2762/4885CYP3A4 3394/4885 |
| US-11896672-B2 | Targeted nucleic acid conjugate compositions | HAVCR2, DCTD, POLRMT | HDAC6 2204/4885ALDH1A1 2585/4885CYP3A4 4125/4885 |
| US-20220031847-A1 | THERAPEUTIC METHODS | NUP205, HNRNPH3, FUS | HDAC6 390/4885ALDH1A1 4243/4885CYP3A4 4878/4885 |
| US-20240245784-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | HAVCR2, DCTD, POLRMT | HDAC6 2204/4885ALDH1A1 2585/4885CYP3A4 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.